GH Research's (GHRS) Sell (D-) Rating Reiterated at Weiss Ratings

GH Research (NASDAQ:GHRS - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

GHRS has been the subject of a number of other reports. Wall Street Zen upgraded GH Research from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. JMP Securities reiterated a "market outperform" rating and set a $39.00 target price on shares of GH Research in a research report on Tuesday, June 24th. Finally, Zacks Research downgraded GH Research from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 13th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $32.00.

GH Research Price Performance

GHRS stock opened at $13.17 on Wednesday. GH Research has a 1-year low of $6.19 and a 1-year high of $20.50. The company has a market capitalization of $685.24 million, a price-to-earnings ratio of -17.80 and a beta of 0.97. The business has a 50 day simple moving average of $13.21 and a two-hundred day simple moving average of $12.45.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. Sell-side analysts anticipate that GH Research will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

Several institutional investors have recently made changes to their positions in GHRS. Osaic Holdings Inc. boosted its position in GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company's stock valued at $75,000 after purchasing an additional 2,400 shares in the last quarter. AdvisorShares Investments LLC boosted its position in GH Research by 15.0% during the second quarter. AdvisorShares Investments LLC now owns 38,256 shares of the company's stock valued at $466,000 after purchasing an additional 5,000 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in GH Research during the second quarter valued at about $79,000. Virtus Investment Advisers LLC bought a new stake in GH Research during the second quarter valued at about $89,000. Finally, Palumbo Wealth Management LLC boosted its position in GH Research by 68.2% during the second quarter. Palumbo Wealth Management LLC now owns 21,651 shares of the company's stock valued at $264,000 after purchasing an additional 8,782 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.